SKB BIO-B(06990)
260.000-4.200-1.59%
Login to post
- CommunityCommunity
- NewsNews
- ProfileProfile
- AnnouncementsAnnouncements
- BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Subscribes For Structured DepositsBRIEF-Sichuan Kelun-Biotech Biopharmaceutical Subscribes For Structured Deposits
Reuters · 03-20 15:27
- Sichuan Kelun-Biotech Biopharmaceutical - Co to Subscribe for 2 Structured Deposits From Bocd Each in Principal Amount of RMB50 MlnSichuan Kelun-Biotech Biopharmaceutical - Co to Subscribe for 2 Structured Deposits From Bocd Each in Principal Amount of RMB50 Mln
THOMSON REUTERS · 03-20 14:36
- SKB Biopharma Gets Marketing Go-Ahead for Second Indication of Cancer DrugSKB Biopharma Gets Marketing Go-Ahead for Second Indication of Cancer Drug
MT Newswires Live · 03-11
- BRIEF-Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved For Marketing In Second Indication By NMPA For EGFRm NSCLCBRIEF-Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved For Marketing In Second Indication By NMPA For EGFRm NSCLC
Reuters · 03-10
- Kelun-Biotech's Trop2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing in Second Indication by Nmpa for Egfrm NsclcKelun-Biotech's Trop2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing in Second Indication by Nmpa for Egfrm Nsclc
THOMSON REUTERS · 03-10
- Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing for Second Indication by NmpaSichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing for Second Indication by Nmpa
THOMSON REUTERS · 03-10
- HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases AntibodyHBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody
MT Newswires Live · 03-06
- Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at BuyNomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy
MT Newswires Live · 02-18
- SKB Biotech Biopharma to Present Results of Phase 1/2 Study of Cancer Drug at US Oncology MeetingSKB Biotech Biopharma to Present Results of Phase 1/2 Study of Cancer Drug at US Oncology Meeting
MT Newswires Live · 02-11
- BRIEF-Sichuan Kelun-Biotech Says Cetuximab N01 Injection Approved For Marketing By NMPA ChinaBRIEF-Sichuan Kelun-Biotech Says Cetuximab N01 Injection Approved For Marketing By NMPA China
Reuters · 02-07
- SKB Biopharma Gets China Nod for Marketing of Cancer DrugSKB Biopharma Gets China Nod for Marketing of Cancer Drug
MT Newswires Live · 02-07
- Sichuan Kelun-Biotech Biopharmaceutical - Cetuximab N01 Injection Approved for Marketing by Nmpa ChinaSichuan Kelun-Biotech Biopharmaceutical - Cetuximab N01 Injection Approved for Marketing by Nmpa China
THOMSON REUTERS · 02-07
- SKB Biopharmaceutical to Continue Leasing Property, Equipment from Controlling ShareholderSKB Biopharmaceutical to Continue Leasing Property, Equipment from Controlling Shareholder
MT Newswires Live · 02-03
- Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic NpcKelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc
THOMSON REUTERS · 01-23
- BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For Structured Deposit From CITIC BankBRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For Structured Deposit From CITIC Bank
Reuters · 01-22
- Sichuan Kelun-Biotech Biopharmaceutical - to Subscribe for Structured Deposit From CITIC Bank in Principal Amount of RMB50 MlnSichuan Kelun-Biotech Biopharmaceutical - to Subscribe for Structured Deposit From CITIC Bank in Principal Amount of RMB50 Mln
THOMSON REUTERS · 01-21
- SKB Biopharmaceutical Gets Marketing Nod for Anti-Tumor Drug in ChinaSKB Biopharmaceutical Gets Marketing Nod for Anti-Tumor Drug in China
MT Newswires Live · 01-21
- Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors DrugSichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug
MT Newswires Live · 01-21
- BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Drug Approval For SKB445 By NMPA ChinaBRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Drug Approval For SKB445 By NMPA China
Reuters · 01-20
- BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPABRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA
Reuters · 01-20
Loading ...
High
266.000
Open
266.000
Volume%
2.48
Low
247.800
Close
264.200
T/O Rate
0.61%
抱歉，当前请求异常(-1)
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial